Risk factors and outcomes of asparaginase-associated pancreatitis in pediatric patients with ALL
- 13 November 2025
- journal article
- Published by American Society of Hematology in Blood
- Vol. 146 (20) , 2417-2427
Abstract
Asparaginase-associated pancreatitis (AAP) is a significant complication in pediatric acute lymphoblastic leukemia (ALL) therapy, often leading to treatment delays or discontinuation. This study aimed to identify AAP risk factors, assess outcomes after first and second episodes, and evaluate the impact of asparaginase rechallenge. We retrospectively analyzed 7640 patients (aged 1 month to 18 years) treated under the Chinese Children Cancer Group ALL 2015 protocol. Patients were stratified as low risk (LR), intermediate risk (IR), or high risk (HR) based on clinical features and measurable residual disease (MRD). AAP was categorized as early or late onset depending on treatment phase. Older age and IR/HR status were independent risk factors for AAP. The cumulative AAP incidence was 2.2% in LR and 5.8% in IR/HR groups. Among 298 patients who developed AAP, 92 were rechallenged with asparaginase; second episodes occurred in 20.8% of LR and 33.8% of IR/HR patients, with no increase in severity. Lack of rechallenge and day 46 MRD of ≥0.01% were independently associated with inferior event-free survival (EFS). Among patients with early-onset AAP, those who were rechallenged had superior 5-year EFS than those who were not rechallenged (80.1% vs 60.2%; P = .003). Similarly, among IR/HR group, those who were rechallenged had better 5-year EFS than those who were not rechallenged (82.4% vs 60.6%; P = .004). IR/HR patients with early-onset AAP who were not rechallenged had especially poor outcomes (5-year EFS, 53.3%). These findings support considering asparaginase rechallenge in IR/HR patients with early-onset AAP when alternative therapies are limited. This trial was registered at www.chictr.org.cn as #ChiCTR2000032211.Keywords
This publication has 15 references indexed in Scilit:
- Prognostic and therapeutic implications of measurable residual disease levels during remission induction of childhood ALLBlood, 2025
- Pulse therapy with vincristine and dexamethasone for childhood acute lymphoblastic leukaemia (CCCG-ALL-2015): an open-label, multicentre, randomised, phase 3, non-inferiority trialThe Lancet Oncology, 2021
- Prognostic factors for CNS control in children with acute lymphoblastic leukemia treated without cranial irradiationBlood, 2021
- Risk Factors for Asparaginase-associated PancreatitisJournal of Clinical Gastroenterology, 2017
- Asparaginase-associated pancreatitis in childhood acute lymphoblastic leukaemia: an observational Ponte di Legno Toxicity Working Group studyThe Lancet Oncology, 2017
- Asparaginase-associated pancreatitis in children with acute lymphoblastic leukaemia in the NOPHO ALL2008 protocolBritish Journal of Haematology, 2014
- Incidence and outcome of pancreatitis in children and young adults with acute lymphoblastic leukaemia treated on a contemporary protocol, UKALL 2003British Journal of Haematology, 2013
- Intravenous PEG-asparaginase during remission induction in children and adolescents with newly diagnosed acute lymphoblastic leukemiaBlood, 2010
- Acute Pancreatitis in Children With Acute Lymphoblastic Leukemia After ChemotherapyJournal of Pediatric Hematology/Oncology, 2009
- Clinical course and outcome in children with acute lymphoblastic leukemia and asparaginase‐associated pancreatitisPediatric Blood & Cancer, 2009